Guardant Health (GH) Scheduled to Post Quarterly Earnings on Thursday

Guardant Health (NASDAQ:GH) will post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Guardant Health to post earnings of ($0.72) per share for the quarter. Guardant Health has set its FY 2024 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. The business had revenue of $155.05 million for the quarter, compared to the consensus estimate of $151.71 million. On average, analysts expect Guardant Health to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Guardant Health Stock Performance

Shares of GH stock opened at $18.82 on Wednesday. Guardant Health has a 12 month low of $15.81 and a 12 month high of $41.06. The stock has a market cap of $2.29 billion, a PE ratio of -4.40 and a beta of 0.92. The company has a current ratio of 6.54, a quick ratio of 6.24 and a debt-to-equity ratio of 7.18. The company’s fifty day moving average price is $18.35 and its 200-day moving average price is $22.40.

Insiders Place Their Bets

In other Guardant Health news, insider Kumud Kalia bought 2,187 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was acquired at an average price of $17.82 per share, with a total value of $38,972.34. Following the transaction, the insider now owns 12,722 shares in the company, valued at $226,706.04. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 6.20% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on GH. Canaccord Genuity Group dropped their target price on shares of Guardant Health from $45.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, April 29th. JPMorgan Chase & Co. dropped their target price on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Guggenheim reiterated a “neutral” rating on shares of Guardant Health in a research note on Friday, April 5th. The Goldman Sachs Group dropped their price target on shares of Guardant Health from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, April 15th. Finally, Piper Sandler dropped their price target on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, February 26th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.70.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.